vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and STURM RUGER & CO INC (RGR). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($196.9M vs $151.1M, roughly 1.3× STURM RUGER & CO INC). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs 3.6%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $12.3M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs 5.1%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Sturm, Ruger & Company, Inc., better known by the shortened name Ruger, is an American firearm manufacturing company based in Southport, Connecticut, with production facilities also in Newport, New Hampshire; Mayodan, North Carolina; and Prescott, Arizona. The company was founded in 1949 by Alexander McCormick Sturm and William B. Ruger and has been publicly traded since 1969.
PCRX vs RGR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.9M | $151.1M |
| Net Profit | — | — |
| Gross Margin | 79.5% | 17.8% |
| Operating Margin | 1.2% | 2.3% |
| Net Margin | — | — |
| Revenue YoY | 5.1% | 3.6% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.05 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.9M | $151.1M | ||
| Q3 25 | $179.5M | $126.8M | ||
| Q2 25 | $181.1M | $132.5M | ||
| Q1 25 | $168.9M | $135.7M | ||
| Q4 24 | $187.3M | $145.8M | ||
| Q3 24 | $168.6M | $122.3M | ||
| Q2 24 | $178.0M | $130.8M | ||
| Q1 24 | $167.1M | $136.8M |
| Q4 25 | — | — | ||
| Q3 25 | $5.4M | $1.6M | ||
| Q2 25 | $-4.8M | $-17.2M | ||
| Q1 25 | $4.8M | $7.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-143.5M | $4.7M | ||
| Q2 24 | $18.9M | $8.3M | ||
| Q1 24 | $9.0M | $7.1M |
| Q4 25 | 79.5% | 17.8% | ||
| Q3 25 | 80.9% | 15.1% | ||
| Q2 25 | 77.4% | 3.9% | ||
| Q1 25 | 79.7% | 22.0% | ||
| Q4 24 | 78.7% | 22.8% | ||
| Q3 24 | 76.9% | 18.5% | ||
| Q2 24 | 75.1% | 22.3% | ||
| Q1 24 | 71.6% | 21.5% |
| Q4 25 | 1.2% | 2.3% | ||
| Q3 25 | 3.5% | -2.7% | ||
| Q2 25 | 4.7% | -15.6% | ||
| Q1 25 | 1.2% | 6.2% | ||
| Q4 24 | 13.2% | 7.8% | ||
| Q3 24 | -82.8% | 3.1% | ||
| Q2 24 | 15.9% | 6.9% | ||
| Q1 24 | 7.9% | 5.5% |
| Q4 25 | — | — | ||
| Q3 25 | 3.0% | 1.2% | ||
| Q2 25 | -2.7% | -13.0% | ||
| Q1 25 | 2.8% | 5.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -85.1% | 3.9% | ||
| Q2 24 | 10.6% | 6.3% | ||
| Q1 24 | 5.4% | 5.2% |
| Q4 25 | $0.05 | $0.22 | ||
| Q3 25 | $0.12 | $0.10 | ||
| Q2 25 | $-0.11 | $-1.05 | ||
| Q1 25 | $0.10 | $0.46 | ||
| Q4 24 | $0.38 | $0.62 | ||
| Q3 24 | $-3.11 | $0.28 | ||
| Q2 24 | $0.39 | $0.47 | ||
| Q1 24 | $0.19 | $0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $238.4M | $92.5M |
| Total DebtLower is stronger | $372.2M | — |
| Stockholders' EquityBook value | $693.1M | $283.8M |
| Total Assets | $1.3B | $342.0M |
| Debt / EquityLower = less leverage | 0.54× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $238.4M | $92.5M | ||
| Q3 25 | $246.3M | $80.8M | ||
| Q2 25 | $445.9M | $101.4M | ||
| Q1 25 | $493.6M | $108.3M | ||
| Q4 24 | $484.6M | $105.5M | ||
| Q3 24 | $453.8M | $96.0M | ||
| Q2 24 | $404.2M | $105.6M | ||
| Q1 24 | $325.9M | $115.3M |
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $693.1M | $283.8M | ||
| Q3 25 | $727.2M | $279.6M | ||
| Q2 25 | $757.8M | $289.3M | ||
| Q1 25 | $798.5M | $321.5M | ||
| Q4 24 | $778.3M | $319.6M | ||
| Q3 24 | $749.6M | $314.9M | ||
| Q2 24 | $879.3M | $321.5M | ||
| Q1 24 | $892.2M | $332.0M |
| Q4 25 | $1.3B | $342.0M | ||
| Q3 25 | $1.3B | $342.3M | ||
| Q2 25 | $1.5B | $349.5M | ||
| Q1 25 | $1.6B | $379.0M | ||
| Q4 24 | $1.6B | $384.0M | ||
| Q3 24 | $1.5B | $373.5M | ||
| Q2 24 | $1.6B | $376.7M | ||
| Q1 24 | $1.6B | $385.0M |
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $43.7M | $15.5M |
| Free Cash FlowOCF − Capex | $43.5M | $12.3M |
| FCF MarginFCF / Revenue | 22.1% | 8.2% |
| Capex IntensityCapex / Revenue | 0.1% | 2.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $136.7M | $38.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $43.7M | $15.5M | ||
| Q3 25 | $60.8M | $12.9M | ||
| Q2 25 | $12.0M | $14.7M | ||
| Q1 25 | $35.5M | $11.1M | ||
| Q4 24 | $33.1M | $20.0M | ||
| Q3 24 | $53.9M | $9.4M | ||
| Q2 24 | $53.2M | $18.7M | ||
| Q1 24 | $49.1M | $7.3M |
| Q4 25 | $43.5M | $12.3M | ||
| Q3 25 | $57.0M | $7.0M | ||
| Q2 25 | $9.3M | $9.1M | ||
| Q1 25 | $26.9M | $10.0M | ||
| Q4 24 | $31.0M | $16.4M | ||
| Q3 24 | $49.8M | $2.6M | ||
| Q2 24 | $51.6M | $10.1M | ||
| Q1 24 | $46.3M | $5.6M |
| Q4 25 | 22.1% | 8.2% | ||
| Q3 25 | 31.7% | 5.5% | ||
| Q2 25 | 5.1% | 6.9% | ||
| Q1 25 | 15.9% | 7.4% | ||
| Q4 24 | 16.6% | 11.2% | ||
| Q3 24 | 29.6% | 2.1% | ||
| Q2 24 | 29.0% | 7.7% | ||
| Q1 24 | 27.7% | 4.1% |
| Q4 25 | 0.1% | 2.1% | ||
| Q3 25 | 2.2% | 4.6% | ||
| Q2 25 | 1.5% | 4.2% | ||
| Q1 25 | 5.1% | 0.8% | ||
| Q4 24 | 1.1% | 2.5% | ||
| Q3 24 | 2.4% | 5.5% | ||
| Q2 24 | 0.9% | 6.6% | ||
| Q1 24 | 1.7% | 1.3% |
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | 2.82× | 2.27× | ||
| Q1 24 | 5.47× | 1.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
